Clinical trial
Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART
NCT00196612 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Completed
Key facts
| NCT number | NCT00196612 |
|---|---|
| Title | Once Daily Antiretroviral Therapy in HIV Infected Adults Treated With HAART |
| Official title | Phase II Randomized Trial Comparing Efficacy and Safety of the Maintenance of a HAART Association Protease Inhibitor Containing Versus a Once Daily Antiretroviral Triple Association, in HIV Adult Patients With Undetectable Viral Load.ANRS 099 ALIZE |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | Triangle Pharmaceuticals Industry Gilead Sciences Bristol-Myers Squibb Dupont Applied Biosciences |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | emtricitabine, FTC (drug), didanosine, ddI (drug), efavirenz (drug) |
| Enrollment | 350 |
| Start date | Apr 1, 2001 |
| Completion | Sep 1, 2004 |
| First posted | Sep 20, 2005 |
| Last update posted | Sep 20, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: